{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.5","value":"2836"},{"groupId":"OG001","spread":"36.8","value":"2657"},{"groupId":"OG002","spread":"77.4","value":"1880"},{"groupId":"OG003","spread":"109.7","value":"3051"},{"groupId":"OG004","spread":"69.4","value":"2031"},{"groupId":"OG005","spread":"39.4","value":"1701"},{"groupId":"OG006","spread":"116.5","value":"4165"},{"comment":"Geometric coefficient of variation could not be calculated due to small number of participants.","groupId":"OG007","spread":"NA","value":"3898"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.7","value":"20610"},{"groupId":"OG001","spread":"14.9","value":"27710"},{"groupId":"OG003","spread":"77.6","value":"19820"},{"groupId":"OG004","spread":"62.1","value":"19610"},{"groupId":"OG005","spread":"45.6","value":"21810"},{"comment":"Geometric coefficient of variation could not be calculated due to small number of participants.","groupId":"OG006","spread":"NA","value":"25880"},{"comment":"Geometric coefficient of variation could not be calculated due to small number of participants.","groupId":"OG007","spread":"NA","value":"19940"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 1; FT-2102 150 mg BID (Single Agent)"},{"description":"Participants with AML in morphologic CR/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent)"},{"description":"Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG002","title":"Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent)"},{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG003","title":"Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG004","title":"Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.","id":"OG005","title":"Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG006","title":"Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG007","title":"Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included those participants for whom it was possible to calculate at least 1 primary PK parameter and who had no major protocol deviations thought to influence the absorption, distribution, metabolism, and excretion of the FT-2102. Here, Overall Number of Participants Analyzed (N) and number analyzed (n) = participants with available data for specific timepoints.","reportingStatus":"POSTED","timeFrame":"Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)","title":"Phase 2: Area Under the Curve (AUClast) for FT-2102","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}